VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
Dato-DXd: Turning the Tide in 70% of Refractory Breast Cancer Cases Where Immunotherapy Falls Short
Dato-DXd: Turning the Tide in 70% of Refractory Breast Cancer Cases Where Immunotherapy Falls Short
May 25, 2026 17:30 CST Updated May 26, 03:11
Share:
